Jason Candreva, Ph.D.
About Jason Candreva, Ph.D.
Jason Candreva, Ph.D., is a Senior Scientist at Bristol Myers Squibb in New Brunswick, New Jersey, specializing in early-phase method development and characterization for biologics.
Company
Jason Candreva, Ph.D., is currently employed at Bristol Myers Squibb, a global biopharmaceutical company. He serves as a Senior Scientist in the R&D team located in New Brunswick, New Jersey, United States. His role involves early-phase method development and characterization for biologics, contributing to the advancements in the bio-pharmaceutical field.
Title
Jason Candreva holds the position of Senior Scientist at Bristol Myers Squibb. In this role, he specializes in early-phase method development and characterization for biologics, utilizing his extensive expertise in biomolecular and protein engineering.
Education and Expertise
Jason Candreva earned his Ph.D. in Chemical Engineering from New York University (NYU) in 2018, after five years of dedicated study and research. He also holds an M.S. in Chemical Engineering from Columbia University, achieved in 2011. His undergraduate studies were completed at Stony Brook University, where he specialized in pharmacology and earned a B.E. in Chemical Engineering in 2010.
Professional Background
Jason Candreva's professional journey includes significant roles in both academia and industry. He worked at NYU Tandon School of Engineering as a Graduate Research Assistant from 2013 to 2018 and was a Scientist at Bristol Myers Squibb from 2018 to 2021. His experience also includes research positions at Brookhaven National Laboratory, Columbia University, Stony Brook University, and a brief stint at Estee Lauder as a Formulation Chemist Intern. Earlier in his career, he participated in a biodiesel production project at Yellow Trading, Ltd. and conducted summer research at the University of Missouri as a high school student.
Research and Specialization
Jason Candreva has a robust background in chemical engineering with a specialization in pharmacology. His research focuses on the bio-pharmaceutical field, particularly in biomolecular and protein engineering. At Bristol Myers Squibb, he is engaged in developing and characterizing biologics, leveraging his expertise to push the boundaries of early-phase method development.